Drug Profile
Research programme: gonadotrophin releasing hormone antagonists - Agouron/Alanex
Alternative Names: Gonadotrophin releasing hormone antagonists research programme - AlanexLatest Information Update: 23 Aug 2006
Price :
$50
*
At a glance
- Originator Alanex Corporation
- Class
- Mechanism of Action Gonadotropin releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Endometriosis
Most Recent Events
- 21 Jun 2000 Warner-Lambert has merged with Pfizer
- 24 May 1999 Agouron acquired by Warner-Lambert
- 21 Oct 1997 Preclinical development for Cancer in USA (Unknown route)